Browsing by Author Gogas, Helen

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)Citation
2015Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsKefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Pupo, Gulietta; Rizos, Helen; Scolyer, Richard; Thompson, John; Becker, Jurgen C; Berking, Carola; Eroglu, Zeynep; et al, Various; Gogas, Helen; Gutzmer, R.; Johnson, Douglas B; Sucker, Antje; Ye, Fei; Zhao, Shilin; Zimmer, Lisa; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: Pathology; Central Clinical School: SurgeryAcquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms, European Journal of Cancer, vol.51, 18, 2015,pp 2792-2799
2017Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanomaLong, Georgina; Arance, Ana; Chiarion-Sileni, Vanna; Cowey, C. Lance; Dalle, S; Del Vecchio, M; et al, Various; Gogas, Helen; Mandala, Mario; Schenker, Michael; Weber, Jeffrey; Northern Clinical School: MedicineAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma, New England Journal of Medicine, vol.377, 19, 2017,pp 1824-1835
2014Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreCombined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, The New England Journal of Medicine, vol.371, 20, 2014,pp 1877-1888
2015Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreDabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, 9992, 2015,pp 444-451
2017Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyLong, Georgina; De Braud, Filippo; et al, Various; Flaherty, K; Garbe, C; Gogas, Helen; Hauschild, Axel; Jouary, Thomas; Larkin, J; Levchenko, Evgeny; Stroyakovskiy, Daniil; Northern Clinical School: MedicineDabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study, Annals of Oncology, vol.28, 7, 2017,pp 1631-1639
2012FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th 2011”Kefford, Richard (Rick); Ascierto, Paolo; Curti, Brendan; et al, Various; Faries, Mark B.; Ferrone, Soldano; Flaherty, Keith; Fox, Bernard; Gajewski, Thomas; Gershenwald, Jeffrey E.; Gogas, Helen; Grimaldi, Antonio; Western Clinical School: Westmead Millennium InstituteFUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th 2011”, Journal of Translational Medicine, vol.10, May, 2012,pp 1-17
2015Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaLong, Georgina; Amonkar, Mayur M; Bondarenko, Igor; de Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Lebbe, Celeste; Levchenko, Evgeny; Schadendorf, Dirk; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreHealth-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma, European Journal of Cancer, vol.51, 7, 2015,pp 833-840
2012New challenges in endpoints for drug development in advanced melanomaHersey, Peter; Flaherty, Keith; Gogas, Helen; Kirkwood, John M; Middleton, Mark; Ribas, Antoni; Sondak, Vernon; Northern Clinical School: SurgeryNew challenges in endpoints for drug development in advanced melanoma, Clinical Cancer Research, vol.18, 2, 2012,pp 336-341
2013Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaKefford, Richard (Rick); et al, Various; Garbe, Claus; Gogas, Helen; Haanen, John; Linette, Gerald; Lorigan, Paul; Marmol, Maribel; Marshall, Margaret A.; Punt, Cornelis J.A.; Ribas, Antoni; Schachter, Jacob; Western Clinical School: Westmead Millennium InstitutePhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, Journal of Clinical Oncology, vol.31, 5, 2013,pp 616-622
2015Treatment algorithms in stage IV melanomaKefford, Richard (Rick); Dummer, R; Eggermont, Alexander; Espinosa, E; Gogas, Helen; Grob, Jean-Jacques; Hauschild, Axel; Martin-Algarra, Salvador; Robert, C; Rutkowski, Piotr; Schadendorf, D; Western Clinical School: Westmead Institute for Medical ResTreatment algorithms in stage IV melanoma, American Journal of Therapeutics, vol.22, 1, 2015,pp 61-67